Takakuwa Orthopaedic Nagayama Clinic

Asahikawa, Japan

Takakuwa Orthopaedic Nagayama Clinic

Asahikawa, Japan
SEARCH FILTERS
Time filter
Source Type

Takakuwa M.,Takakuwa Orthopaedic Nagayama Clinic | Iwamoto J.,Keio University
Biological and Pharmaceutical Bulletin | Year: 2012

Intramuscularly administered elcatonin (ECT) reduces pain via the central nervous system. A prospective study was performed to determine whether ECT has a beneficial effect on back pain and function in postmenopausal women with osteoporosis during bisphosphonate therapy. Sixty-one postmenopausal osteoporotic women with back pain (mean age: 73.7 years, range: 54-96 years) were divided into two groups: the control group (n=30) and the ECT (intramuscular, 20 units a week) group (n=31). All patients received treatment with risedronate (17.5 mg weekly). The duration of the study was 8 weeks. Urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX), visual analogue scale (VAS) for back pain at rest and movement, and Roland-Morris Disability Questionnaire (RDQ) score for function were assessed. Urinary NTX levels, VAS at rest and movement, and RDQ score markedly decreased during 8 weeks of treatment in both ECT and control groups. A significant reduction in VAS at movement, but not in VAS at rest and RDQ score, was noted in the ECT group than in the control group. This effect was observed from 2 weeks after the start of therapy. These results suggested that ECT in combination with risedronate was more effective than risedronate alone for reducing back pain in postmenopausal women with osteoporosis. © 2012 The Pharmaceutical Society of Japan.


Takakuwa M.,Takakuwa Orthopaedic Nagayama Clinic | Konishi M.,General Electric | Zhou Q.,General Electric | Itabashi K.,Eisai Co.
Journal of Bone and Mineral Metabolism | Year: 2011

The purpose of this practice-based observational study was to clarify the acute effect of risedronate on proximal femur bone mineral density (BMD) and structural geometry in patients with an increased risk of fractures. One hundred sixty-four patients (7 men and 157 postmenopausal women; mean age, 69.2 years) with osteoporosis or osteopenia and clinical risk factors of fractures were analyzed. All these patients were treated with risedronate for 1 year. Urinary levels of cross-linked N-terminal telopeptide of type I collagen (NTX) were measured at baseline and 4 months after the start of treatment. BMD of the lumbar spine and proximal femur and structural geometric parameters of the proximal femur were evaluated by dual-energy X-ray absorptiometry with advanced hip assessment (AHA) software at baseline and every 4 months. Urinary NTX levels significantly decreased after 4 months of treatment. BMD of the femoral neck and total hip significantly increased after 4, 8, and 12 months of treatment. Cross-sectional moment of inertia (CSMI) and cross-sectional area significantly increased after 4, 8, and 12 months of treatment. An increase in CSMI was apparently greater than those of proximal femur BMD after 4 months of treatment. These results suggest the acute (4 months) and sustained (12 months) effect of risedronate on proximal femur structural geometry as well as BMD as a result of suppression of bone resorption in patients with an increased risk of fractures. © 2010 The Japanese Society for Bone and Mineral Research and Springer.


Takakuwa M.,Takakuwa Orthopaedic Nagayama Clinic | Iwamoto J.,Keio University | Itabashi K.,Eisai Co.
Clinical Drug Investigation | Year: 2012

Background and Objective: We previously reported that risedronate improved the structural parameters of the proximal femur, as well as lumbar spine and proximal femoral bone mineral density (BMD), after 1 year of therapy by suppressing bone resorption in patients with an increased risk of fracture. Our practice-based observational study was subsequently extended to determine whether these effects were enhanced, maintained or attenuated after 3 years. Methods: A total of 174 patients (nine men and 165 postmenopausal women) with a mean age of 67.8 years who had osteoporosis or osteopenia and clinical risk factors for fracture started risedronate therapy. The BMD of the lumbar spine and proximal femur, as well as proximal femoral structural parameters, were evaluated by dual-energy x-ray absorptiometry with advanced hip assessment (AHA) software at baseline and every year for 3 years. Results: Data were available for 107 patients at 1 year, 80 patients at 2 years and 74 patients at 3 years. Lumbar spine, total hip and femoral neck BMD and the cross-sectional area (CSA) of the proximal femur increased from baseline after 1 year with levels being maintained after 2-3 years. The crosssectional moment of inertia (CSMI) of the proximal femur increased from baseline after 1 year and the increase was enhanced after 2 years with levels being maintained after 3 years. The femoral strength index (FSI) increased from baseline after 1 and 2 years and the increase was enhanced after 3 years. The increases in proximal femoral CSMI and FSI were greater than those of total hip and femoral neck BMD after 3 years of therapy. Conclusion: The present study showed the effects of risedronate therapy for 3 years on the BMD of the lumbar spine and proximal femur, as well as on proximal femoral structure, in patients with an increased risk for fracture. © 2012 Adis Data Information BV. All rights reserved.


Osugi T.,Takakuwa Orthopaedic Nagayama Clinic | Iwamoto J.,Keio University | Yamazaki M.,Takakuwa Orthopaedic Nagayama Clinic | Takakuwa M.,Takakuwa Orthopaedic Nagayama Clinic
Therapeutics and Clinical Risk Management | Year: 2014

A randomized controlled trial was conducted to clarify the beneficial effect of whole body vibration (WBV) exercise plus squat training on body balance, muscle power, and walking ability in the elderly with knee osteoarthritis and/or spondylosis. Of 35 ambulatory patients (14 men and 21 women) who were recruited at our outpatient clinic, 28 (80.0%, 12 men and 16 women) participated in the trial. The subjects (mean age 72.4 years) were randomly divided into two groups (n=14 in each group), ie, a WBV exercise alone group and a WBV exercise plus squat training group. A 4-minute WBV exercise (frequency 20 Hz) was performed 2 days per week in both groups; squat training (20 times per minute) was added during the 4-minute WBV training session in the WBV exercise plus squat training group. The duration of the trial was 6 months. The exercise and training program was safe and well tolerated. WBV exercise alone improved indices of body balance and walking velocity from baseline values. However, WBV exercise plus squat training was more effective for improving tandem gait step number and chair-rising time compared with WBV exercise alone. These results suggest the benefit and safety of WBV exercise plus squat training for improving physical function in terms of body balance and muscle power in the elderly. © 2014 Osugi et al.


Takakuwaa M.,Takakuwa Orthopaedic Nagayama Clinic | Iwamoto J.,Keio University
Biological and Pharmaceutical Bulletin | Year: 2015

The purpose of this practice-based observational study was to examine the effects of long-term treatment with risedronate in patients with an increased fracture risk. Seventy patients (4 men and 66 postmenopausal women; mean age, 68.0 years) with osteoporosis or osteopenia and clinical risk factors for fractures were treated with risedronate at either 2.5 mg/d or 17.5 mg/week for 5 years. The bone mineral density (BMD) of the lumbar spine and proximal femur, and the structural geometric parameters of the proximal femur were evaluated by dual-energy X-ray absorptiometry with advanced hip assessment software at baseline and after each year of treatment. The lumbar spine BMD rapidly increased during the first year of the treatment and steadily increased throughout the 5-year treatment period. The BMD of the femoral neck and total hip also significantly increased during the first 3 and 2 years of treatment, respectively, then gradually declined and reached the baseline level after 5 years of treatment. The cross-sectional moment of inertia, cross-sectional area, and mean width of the femoral neck region of interest significantly increased during the first 2 years, and these increases were maintained throughout the 5-year treatment period. The femur strength index and section modulus also significantly increased following time courses similar to those of the above three parameters. These results suggest that risedronate produced both a sustained increase in the lumbar spine BMD and improvement in the femoral structural geometric parameters for 5 years of treatment. © 2015 The Pharmaceutical Society of Japan.


Yamashita F.,Takakuwa Orthopaedic Nagayama Clinic | Iwamoto J.,Keio University | Osugi T.,Takakuwa Orthopaedic Nagayama Clinic | Yamazaki M.,Takakuwa Orthopaedic Nagayama Clinic | Takakuwa M.,Takakuwa Orthopaedic Nagayama Clinic
Journal of Musculoskeletal Neuronal Interactions | Year: 2012

A randomized controlled trial was conducted to compare the effect of a one-leg standing exercise and a chair-rising exercise on body balance in patients with locomotive disorders. Thirty ambulatory patients (mean age: 66.6 years) were randomly divided into two groups (n=15 in each group): a one-leg standing exercise group and a chair-rising exercise group. All the participants performed calisthenics of the major muscles, a tandem gait exercise, and a stepping exercise. The exercises were performed 3 days per week, and the study period was 5 months. Physical function was evaluated at baseline and at one-month intervals. No significant differences in the baseline characteristics were observed between the two groups. After the 5-month exercise program, the timed up & go, one-leg standing time, and tandem gait time improved significantly in the one-leg standing exercise group, while the walking time and chair-rising time in addition to above parameters improved significantly in the chair-rising exercise group. The improvements in the walking time, chair-rising time, and tandem gait time were significantly greater in the chair-rising exercise group than in the one-leg standing exercise group. The present study showed that the chair-rising exercise was more effective than the one-leg standing exercise for improving walking velocity and dynamic body balance.


PubMed | Takakuwa Orthopaedic Nagayama Clinic
Type: Journal Article | Journal: Clinical drug investigation | Year: 2012

We previously reported that risedronate improved the structural parameters of the proximal femur, as well as lumbar spine and proximal femoral bone mineral density (BMD), after 1 year of therapy by suppressing bone resorption in patients with an increased risk of fracture. Our practice-based observational study was subsequently extended to determine whether these effects were enhanced, maintained or attenuated after 3 years.A total of 174 patients (nine men and 165 postmenopausal women) with a mean age of 67.8 years who had osteoporosis or osteopenia and clinical risk factors for fracture started risedronate therapy. The BMD of the lumbar spine and proximal femur, as well as proximal femoral structural parameters, were evaluated by dual-energy x-ray absorptiometry with advanced hip assessment (AHA) software at baseline and every year for 3 years.Data were available for 107 patients at 1 year, 80 patients at 2 years and 74 patients at 3 years. Lumbar spine, total hip and femoral neck BMD and the cross-sectional area (CSA) of the proximal femur increased from baseline after 1 year with levels being maintained after 2-3 years. The cross-sectional moment of inertia (CSMI) of the proximal femur increased from baseline after 1 year and the increase was enhanced after 2 years with levels being maintained after 3 years. The femoral strength index (FSI) increased from baseline after 1 and 2 years and the increase was enhanced after 3 years. The increases in proximal femoral CSMI and FSI were greater than those of total hip and femoral neck BMD after 3 years of therapy.The present study showed the effects of risedronate therapy for 3 years on the BMD of the lumbar spine and proximal femur, as well as on proximal femoral structure, in patients with an increased risk for fracture.


PubMed | Takakuwa Orthopaedic Nagayama Clinic
Type: Comparative Study | Journal: Journal of musculoskeletal & neuronal interactions | Year: 2012

A randomized controlled trial was conducted to compare the effect of a one-leg standing exercise and a chair-rising exercise on body balance in patients with locomotive disorders. Thirty ambulatory patients (mean age: 66.6 years) were randomly divided into two groups (n=15 in each group): a one-leg standing exercise group and a chair-rising exercise group. All the participants performed calisthenics of the major muscles, a tandem gait exercise, and a stepping exercise. The exercises were performed 3 days per week, and the study period was 5 months. Physical function was evaluated at baseline and at one-month intervals. No significant differences in the baseline characteristics were observed between the two groups. After the 5-month exercise program, the timed up and go, one-leg standing time, and tandem gait time improved significantly in the one-leg standing exercise group, while the walking time and chair-rising time in addition to above parameters improved significantly in the chair-rising exercise group. The improvements in the walking time, chair-rising time, and tandem gait time were significantly greater in the chair-rising exercise group than in the one-leg standing exercise group. The present study showed that the chair-rising exercise was more effective than the one-leg standing exercise for improving walking velocity and dynamic body balance.


PubMed | Takakuwa Orthopaedic Nagayama Clinic.
Type: Journal Article | Journal: Biological & pharmaceutical bulletin | Year: 2015

The purpose of this practice-based observational study was to examine the effects of long-term treatment with risedronate in patients with an increased fracture risk. Seventy patients (4 men and 66 postmenopausal women; mean age, 68.0 years) with osteoporosis or osteopenia and clinical risk factors for fractures were treated with risedronate at either 2.5mg/d or 17.5mg/week for 5 years. The bone mineral density (BMD) of the lumbar spine and proximal femur, and the structural geometric parameters of the proximal femur were evaluated by dual-energy X-ray absorptiometry with advanced hip assessment software at baseline and after each year of treatment. The lumbar spine BMD rapidly increased during the first year of the treatment and steadily increased throughout the 5-year treatment period. The BMD of the femoral neck and total hip also significantly increased during the first 3 and 2 years of treatment, respectively, then gradually declined and reached the baseline level after 5 years of treatment. The cross-sectional moment of inertia, cross-sectional area, and mean width of the femoral neck region of interest significantly increased during the first 2 years, and these increases were maintained throughout the 5-year treatment period. The femur strength index and section modulus also significantly increased following time courses similar to those of the above three parameters. These results suggest that risedronate produced both a sustained increase in the lumbar spine BMD and improvement in the femoral structural geometric parameters for 5 years of treatment.


PubMed | Takakuwa Orthopaedic Nagayama Clinic
Type: Journal Article | Journal: Journal of bone and mineral metabolism | Year: 2011

The purpose of this practice-based observational study was to clarify the acute effect of risedronate on proximal femur bone mineral density (BMD) and structural geometry in patients with an increased risk of fractures. One hundred sixty-four patients (7 men and 157 postmenopausal women; mean age, 69.2 years) with osteoporosis or osteopenia and clinical risk factors of fractures were analyzed. All these patients were treated with risedronate for 1 year. Urinary levels of cross-linked N-terminal telopeptide of type I collagen (NTX) were measured at baseline and 4 months after the start of treatment. BMD of the lumbar spine and proximal femur and structural geometric parameters of the proximal femur were evaluated by dual-energy X-ray absorptiometry with advanced hip assessment (AHA) software at baseline and every 4 months. Urinary NTX levels significantly decreased after 4 months of treatment. BMD of the femoral neck and total hip significantly increased after 4, 8, and 12 months of treatment. Cross-sectional moment of inertia (CSMI) and cross-sectional area significantly increased after 4, 8, and 12 months of treatment. An increase in CSMI was apparently greater than those of proximal femur BMD after 4 months of treatment. These results suggest the acute (4 months) and sustained (12 months) effect of risedronate on proximal femur structural geometry as well as BMD as a result of suppression of bone resorption in patients with an increased risk of fractures.

Loading Takakuwa Orthopaedic Nagayama Clinic collaborators
Loading Takakuwa Orthopaedic Nagayama Clinic collaborators